Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erbach – page 25

675 clinical trials in Erbach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erbach at a glance
675
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

675 trials in Erbach

Open in trial search

Psoriasis

Not yet recruiting

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Psoriasis

Not yet recruiting

Phase 2 Study of ABBV-295 and Risankizumab in Adults with Moderate to Severe Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Medizinische Hochschule Hannover

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Safety and Efficacy of GSK5764227 with Abiraterone Acetate and Enzalutamide in Metastatic Castration‑Resistant Prostate Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Glaxosmithkline Research & Development Limited

Major depression

Not yet recruiting

Efficacy and Safety of AGN-151607-DP in Adults with Major Depressive Disorder: A Randomized, Placebo‑Controlled Phase 2 Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erbach

What the registry says about research in the country

01 Alzheimer's Disease Research

Groundbreaking clinical trials focusing on early Alzheimer's disease treatments and interventions for associated psychosis. Studies are evaluating novel compounds for managing cognitive decline and neuropsychiatric symptoms.

  • Early-stage disease intervention
  • Psychosis management
  • Cognitive function preservation

Multiple therapeutic approaches targeting both cognitive symptoms and behavioral manifestations of the disease.

02 Migraine Studies

Innovative research examining new treatments for menstrual migraine and chronic migraine conditions. Comparative studies evaluating the effectiveness of different preventive treatments.

  • Preventive treatment protocols
  • Medication comparison studies
  • Gender-specific approaches

Focus on developing targeted therapies for specific types of migraines and their prevention.

03 Multiple Sclerosis Initiatives

Comprehensive research programs investigating treatments for various forms of multiple sclerosis, including progressive and relapsing forms. Studies utilize advanced imaging techniques to track disease progression.

  • Progressive MS treatments
  • Brain atrophy assessment
  • Disability progression prevention

Advanced therapeutic approaches targeting different disease manifestations and progression patterns.

04 Parkinson's Disease Studies

Innovative research focusing on early-onset Parkinson's disease, examining long-term treatment efficacy and brain pathophysiology changes. Studies aim to understand disease progression and therapeutic interventions.

  • Early intervention strategies
  • Long-term treatment effects
  • Disease modification approaches

Emphasis on understanding disease mechanisms and developing targeted therapeutic solutions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.